Market Overview

UPDATE: Stifel Nicolaus Initiates St. Jude Medical at Hold on Near-Term Headwinds

Related STJ
St. Jude Medical Receives CE Mark Approval For Pacing Lead Labeling That Will Expand Patient Access To MRI Scans
UPDATE: St. Jude Medical Resolves FDA Warning

Stifel Nicolaus initiated coverage on St. Jude Medical (NYSE: STJ) with a Hold rating.

Stifel Nicolaus said, "We are initiating coverage of St. Jude Medical Inc. (STJ) with a Hold rating on the shares. With top-line growth slowing and lingering uncertainties about the impact of the Riata/Durata ICD lead controversy resolution, a possible FDA Warning Letter, and no visible significant near-term positive catalyst, we are inclined to remain on the sidelines, pending greater visibility on these issues."

St. Jude Medical closed at $35.03 on Monday.

Latest Ratings for STJ

DateFirmActionFromTo
Jul 2014Sterne AgeeInitiates Coverage onNeutral
Jul 2014BarclaysMaintainsOverweight
Jul 2014Canaccord GenuityMaintainsSell

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (STJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters